The Effectiveness of Dual-Staining Immunohistochemistry in the Detection of Mantle Cell Lymphoma in the Bone Marrow

被引:0
作者
Obiorah, Ifeyinwa E. [1 ,2 ]
Wang, Hao-Wei [1 ,3 ]
Ma, David [2 ]
Martin, Eddie [2 ]
Wilson, Wyndham H. [2 ,4 ]
Braylan, Raul [2 ]
机构
[1] NCI, Hematopathol Sect Lab Pathol, NIH, Bethesda, MD 20892 USA
[2] Natl Inst Hlth, Hematol Sect, Ctr Clin, Dept Lab Med, Bethesda, MD USA
[3] Natl Canc Inst, Natl Inst Hlth, Flow Cytometry Unit, Pathol Lab, Bethesda, MD USA
[4] Natl Canc Inst, Natl Inst Hlth, Ctr Canc Res, Lymphoid Malignancy Branch, Bethesda, MD USA
基金
美国国家卫生研究院;
关键词
Mantle cell; Lymphoma; Dual staining; Immunohistochemistry; MINIMAL RESIDUAL DISEASE; 8-COLOR FLOW-CYTOMETRY; CYCLIN D1 EXPRESSION; LEUKEMIA; CD103;
D O I
10.1093/ajcp/aqab179
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives Immunohistochemistry (IHC) is a useful method for mantle cell lymphoma (MCL) detection in the bone marrow (BM). However, recognition of the neoplastic B cells can be challenging, especially when there is low-level disease. Methods We examined BM from 105 patients with MCL. IHC was performed using cyclin D1/CD79a and PAX5/CD5 dual stains, which were compared with single stains that included CD20, CD79a, cyclin D1, and CD5 and with multiparameter flow cytometry (FC). Results Based on the FC data, the overall sensitivity of the dual IHC stains was 95.6%. Both dual IHC stains showed better efficacy for detecting MCL cells compared with the aggregated single stains (P = .012). While three cases were positive by FC analysis but negative for dual staining, four cases showed cells positive for cyclin D1/CD79a and PAX5/CD5 dual staining that were not detected by FC. Two of these latter cases were in patients with minimal or focal disease involvement. Conclusions Cyclin D1/CD79a and PAX5/CD5 dual IHC staining is an efficient procedure for the detection of MCL in the marrow and is particularly helpful in low-level or focal involvement by MCL. This approach can be particularly useful when marrow aspirates are inadequate or unavailable.
引用
收藏
页码:709 / 717
页数:9
相关论文
共 30 条
[1]   Immunohistological recognition of cyclin D1 expression by non-lymphoid cells among lymphoid neoplastic cells [J].
Abdulla, Zainalabideen ;
Turley, Helen ;
Gatter, Kevin ;
Pezzella, Francesco .
APMIS, 2014, 122 (03) :183-191
[2]  
[Anonymous], 2007, H43A2 CLSI
[3]  
Bosch F, 1998, CANCER, V82, P567, DOI 10.1002/(SICI)1097-0142(19980201)82:3<567::AID-CNCR20>3.0.CO
[4]  
2-Z
[5]  
Campo E, 1999, SEMIN HEMATOL, V36, P115
[6]   Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study [J].
Cheminant, Morgane ;
Derrieux, Coralie ;
Touzart, Aurore ;
Schmit, Stephanie ;
Grenier, Adrien ;
Trinquand, Amelie ;
Delfau-Larue, Marie-Helene ;
Lhermitte, Ludovic ;
Thieblemont, Catherine ;
Ribrag, Vincent ;
Cheze, Stephane ;
Sanhes, Laurence ;
Jardin, Fabrice ;
Lefrere, Francois ;
Delarue, Richard ;
Hoster, Eva ;
Dreyling, Martin ;
Asnafi, Vahid ;
Hermine, Olivier ;
Macintyre, Elizabeth .
HAEMATOLOGICA, 2016, 101 (03) :336-345
[7]   Detection of Minimal Residual Disease in Mantle Cell Lymphoma-Establishment of Novel Eight-Color Flow Cytometry Approach [J].
Chovancova, Jana ;
Bernard, Tomas ;
Stehlikova, Olga ;
Salek, David ;
Janikova, Andrea ;
Mayer, Jiri ;
Doubek, Michael .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2015, 88 (02) :92-100
[8]   Immunophenotypic Analysis of CD103+ B-Lymphoproliferative Disorders Hairy Cell Leukemia and Its Mimics [J].
Dong, Henry Y. ;
Weisberger, James ;
Liu, Zach ;
Tugulea, Sorina .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 131 (04) :586-595
[9]   How to manage mantle cell lymphoma [J].
Dreyling, M. ;
Ferrero, S. ;
Hermine, O. .
LEUKEMIA, 2014, 28 (11) :2117-2130
[10]   Minimal residual disease in mantle cell lymphoma: are we ready for a personalized treatment approach? [J].
Ferrero, Simone ;
Dreyling, Martin .
HAEMATOLOGICA, 2017, 102 (07) :1133-1136